Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola Mozzillo

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Ecancermedicalscience|March 3, 2015
Report from the second MIB (Melanoma Independent Board) Conference, 27-28 October 2014Alessandro Testori, Carlo Riccardo Rossi, Paolo Ascierto, et al.
Annals of Surgical Oncology|March 17, 2004
Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimetersCorrado Caracò, Egidio Celentano, Secondo Lastoria, et al.
Annals of Surgical Oncology|March 17, 2004
Therapeutic implications of sentinel lymph node biopsy in the staging of oral cancerNicola Mozzillo, Fausto Chiesa, Corrado Caracò, et al.
Journal of Translational Medicine|May 30, 2012
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical usePaolo A Ascierto, Ester Simeone, Diana Giannarelli, et al.
Diagnostic Cytopathology|March 29, 2012
Fine-needle cytology of Kaposi's sarcoma in an intramammary lymphnode: report of one caseFranco Fulciniti, Annarosaria De Chiara, Gaetano Apice, et al.
BMC Cancer|January 16, 2013
Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutationsGiusy Gentilcore, Gabriele Madonna, Nicola Mozzillo, et al.
Journal of Translational Medicine|March 19, 2013
Do BRAF inhibitors select for populations with different disease progression kinetics?Paolo Antonio Ascierto, Ester Simeone, Antonio Maria Grimaldi, et al.
Cancer Immunology, Immunotherapy : CII|September 9, 2016
Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trialPaolo A Ascierto, Vito Vanella, Antonio Maria Grimaldi, et al.
Journal of Human Genetics|June 11, 2010
MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thicknessMario Capasso, Fabrizio Ayala, Rosa Anna Avvisati, et al.
Journal of Medical Case Reports|July 3, 2014
Serious haematological toxicity during and after ipilimumab treatment: a case seriesEster Simeone, Antonio Maria Grimaldi, Assunta Esposito, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Ecancermedicalscience|March 3, 2015
Report from the second MIB (Melanoma Independent Board) Conference, 27-28 October 2014Alessandro Testori, Carlo Riccardo Rossi, Paolo Ascierto, et al.
Annals of Surgical Oncology|March 17, 2004
Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than four millimetersCorrado Caracò, Egidio Celentano, Secondo Lastoria, et al.
Annals of Surgical Oncology|March 17, 2004
Therapeutic implications of sentinel lymph node biopsy in the staging of oral cancerNicola Mozzillo, Fausto Chiesa, Corrado Caracò, et al.
Journal of Translational Medicine|May 30, 2012
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical usePaolo A Ascierto, Ester Simeone, Diana Giannarelli, et al.
Diagnostic Cytopathology|March 29, 2012
Fine-needle cytology of Kaposi's sarcoma in an intramammary lymphnode: report of one caseFranco Fulciniti, Annarosaria De Chiara, Gaetano Apice, et al.
BMC Cancer|January 16, 2013
Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutationsGiusy Gentilcore, Gabriele Madonna, Nicola Mozzillo, et al.
Journal of Translational Medicine|March 19, 2013
Do BRAF inhibitors select for populations with different disease progression kinetics?Paolo Antonio Ascierto, Ester Simeone, Antonio Maria Grimaldi, et al.
Cancer Immunology, Immunotherapy : CII|September 9, 2016
Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trialPaolo A Ascierto, Vito Vanella, Antonio Maria Grimaldi, et al.
Journal of Human Genetics|June 11, 2010
MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thicknessMario Capasso, Fabrizio Ayala, Rosa Anna Avvisati, et al.
Journal of Medical Case Reports|July 3, 2014
Serious haematological toxicity during and after ipilimumab treatment: a case seriesEster Simeone, Antonio Maria Grimaldi, Assunta Esposito, et al.
Pageof 9